Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Prostate Cancer
Prostate Cancer News & Features
Apalutamide Plus ADT for mCSPC Maintains Health-Related Quality of Life
In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
Many Can Avoid RT After Surgery for Localized Prostate Cancer
Progression-free survival no different at five years when radiotherapy is used only if the cancer returns.
Cabazitaxel Superior to Switching Antiandrogens for Third-Line mCRPC Treatment
In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
Long-Term Antiandrogen Therapy With Salvage Radiation May Up Death Risk
In a secondary analysis of NRG Oncology/RTOG 9601, some patients had no survival benefit from long-term antiandrogen treatment.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
